MENS: MCS-2 stands out for safety and innovation, with early FDA phase III approval positioning for market entryQuartr·Sep 7, 2026 at 01:35 AMMENS+4.76%
Jyong Biotech to join StockFan virtual investor non-deal roadshowPUBT·Sep 3, 2026 at 12:02 PMMENS+4.76%
Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships | MENS Stock NewsStockTitan·Jul 23, 2026 at 06:52 AMMENS+4.76%